Current Report Filing (8-k)
25 February 2021 - 2:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 24, 2021
Poseida
Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-39376
|
|
47-2846548
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
9390 Towne Centre Drive, Suite 200
San Diego, California
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (858)
779-3100
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, par value $0.0001 per share
|
|
PSTX
|
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the
Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01
|
Regulation FD Disclosure.
|
On February 24, 2021, members of management of Poseida Therapeutics, Inc. (the Company) and external advisors are providing an update on the
Companys research and development programs and making available the presentation attached as Exhibit 99.1 to this report. The presentation is also available under the Investors section of the Companys website.
The information in this Item 7.01 of this report (including Exhibit 99.1) is furnished and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference
into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after todays date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by
specific references in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Poseida Therapeutics, Inc.
|
|
|
|
|
Date: February 24, 2021
|
|
|
|
By:
|
|
/s/ Harry J. Leonhardt
|
|
|
|
|
|
|
Harry J. Leonhardt
General Counsel and Chief
Compliance Officer
|
Poseida Therapeutics (NASDAQ:PSTX)
Historical Stock Chart
From Apr 2024 to May 2024
Poseida Therapeutics (NASDAQ:PSTX)
Historical Stock Chart
From May 2023 to May 2024